Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases

Gianluca Quaranta, Maurizio Sanguinetti, Luca Masucci, Gianluca Quaranta, Maurizio Sanguinetti, Luca Masucci

Abstract

The gastro-intestinal tract is an extensive organ involved in several activities, with a crucial role in immunity. Billions of commensal and transient microorganisms, known as the gut microbiota, and potential pathogens, which are constantly stimulating intestinal immunity, colonize the intestinal epithelial surface. The gut microbiota may be regarded as analogous to a solid organ with multiple different functions. In the last decade, many studies have demonstrated that intestinal bacteria can be a decisive factor in the health-disease balance of the intestine, and they can also be responsible for illnesses in other locations. For this reason, fecal microbiota transplantation (FMT) represents an important therapeutic option for Clostridium difficile infections and hold promise for different clinical conditions, such as multiple sclerosis, autism, obesity, and other systemic diseases. FMT consists of the infusion of a fecal suspension from a healthy donor to a recipient in order to restore gut flora alterations. Similar to the gut, the female reproductive tract is an example of a very complex biological ecosystem. Recent studies indicate a possible relationship between the gut and female tract microbiota, associating specific intestinal bacteria patterns with genital female diseases, such as polycystic ovary syndrome (PCOS), endometriosis and bacterial vaginosis (BV). FMT could represent a potential innovative treatment option in this field.

Keywords: cervical-vaginal microbiota; fecal microbiota transplant (FMT); gut micobiota; immunmodulation; next generation sequencing (NGS); probiotics; uterine microbiota.

Copyright © 2019 Quaranta, Sanguinetti and Masucci.

Figures

Figure 1
Figure 1
Potential use of FMT in systemic clinical disorders. These diseases are hypothesized being associated to specific gut bacteria alterations (–33).
Figure 2
Figure 2
Gut-Vagina cross-talking. Bacteria and immunity cells in vagina and gut are in close communication. Hormonal changes during menopause, menstruations lead to an overgrowth of anaerobic species such as Gardnerella vaginalis (GV). Bacterial vaginosis (BV), caused by GV, increases an immunity molecules release which exerts pro-inflammatory effects in situ and in the gut. Proteobacteria overgrowth leads to LPS iper-production establishing an inflammatory status. Oral probiotics alleviate BV in women. FMT might play a similar role in regulating both altered gut flora and vagina inflammation (74, 77).

References

    1. Johansson ME, Jakobsson HE, Holmen-Larsson J, Schutte A, Ermund A, Rodriguez-Pineiro AM, et al. . Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe. (2015) 18:582–92. 10.1016/j.chom.2015.10.007
    1. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. . Diversity of the human intestinal microbial flora. Science. (2005) 308:1635–8. 10.1126/science.1110591
    1. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al. . Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. (2015) 42:965–76. 10.1016/j.immuni.2015.04.019
    1. Baker J, Chase D, Herbst-Kralovetz M. Uterine microbiota: residents, tourists, or invaders? Front Immunol. (2018) 9:208 10.3389/fimmu.2018.00208
    1. Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. (2017) 28:324 10.3389/fmicb.2017.00324
    1. Oren A, Rupnik M. Clostridium difficile and clostridioides difficile: two validly published and correct names. Anaerobe. (2018) 52:125–6. 10.1016/j.anaerobe.2018.07.005
    1. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. . European consensus conference on faecal microbiota transplantation in clinical practice. Gut. (2017) 66:569–80. 10.1136/gutjnl-2016-313017
    1. Lagier JC, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F, et al. Culturing the human microbiota and culturomics. Nat Rev Microbiol. (2018) 1:540–50. 10.1038/s41579-018-0041-0
    1. Scarpellini E, Ianiro G, Attili F, Bassanelli C, De Santis A, Gasbarrini A. The human gut microbiota and virome: potential therapeutic implications Dig. Liver Dis. (2015) 47:1007–12. 10.1016/j.dld.2015.07.008
    1. Yadav M, Verma M, Chauhan N. A review of metabolic potential of human gut microbiome in human nutrition. Arch Microbiol. (2018) 200:203–17. 10.1007/s00203-017-1459-x
    1. Kanwar SS, Walia S, Sharma S. Impact of probiotics and gut microbiota on host behavior. In: Garg N, Abdel-Aziz S, Aeron A. editors. Microbes in Food and Health. Cham: Springer; (2016). p. 29–41. 10.1007/978-3-319-25277-3_2
    1. Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE. (2008) 3:e2836. 10.1371/journal.pone.0002836
    1. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. . Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA. (2006) 103:732–7. 10.1073/pnas.0506655103
    1. Paroni F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, et al. Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients. Appl Environ Microbiol. 82:6633–44. 10.1128/AEM.01437-16
    1. Hayashi H, Takahashi R, Nishi T, Sakamoto M, Benno Y. Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol. (2005) 54:1093–101. 10.1099/jmm.0.45935-0
    1. Kumar J, Kumar M, Gupta S, Bhambi M, Pandey R, et al. . An improved methodology to overcome key issues in human fecal metagenomic DNA extraction. Genom Proteom Bioinform. (2016) 14:371–8. 10.1016/j.gpb.2016.06.002
    1. Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther. (2015) 149:191–212. 10.1016/j.pharmthera.2014.12.006
    1. Jørgensen SMD, Hansen MM, Erikstrup C, Dahlerup JF, Hvas CL. Faecal microbiota transplantation: establishment of a clinical application framework. Eur J Gastroenterol Hepatol. (2017) 29:e36–45. 10.1097/MEG.0000000000000958
    1. Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, et al. . Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. (2018) 48:152–9. 10.1111/apt.14816
    1. Filip M, Tzaneva V, Dumitrascu DL. Fecal transplantation: digestive and extradigestive clinical applications. Clujul Med. (2018) 91:259–65. 10.15386/cjmed-946
    1. Ramai D, Zakhia K, Ofosu A, Ofori E, Reddy M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol. (2019) 32:30–8. 10.20524/aog.2018.0328
    1. Takahashi M, Ishikawa D, Sasaki T, Lu YJ, Kuwahara-Arai K, Kamei M, et al. . Faecal freezing preservation period influences colonization ability for faecal microbiota transplantation. J Appl Microbiol. (2019) 126:973–84. 10.1111/jam.14167
    1. Perez E, Lee CH, Petrof EO. A practical method for preparation of fecal microbiota transplantation. Methods Mol Biol. (2016) 1476:259–67. 10.1007/978-1-4939-6361-4_19
    1. Papanicolas LE, Choo JM, Wang Y, Leong LEX, Costello SP, Gordon DL, et al. . Bacterial viability in faecal transplants: which bacteria survive? EBioMedicine. (2019) 41:509–16. 10.1016/j.ebiom.2019.02.023
    1. Kim P, Gadani A, Abdul-Baki H, Mitre R, Mitre M. Fecal microbiota transplantation in recurrent Clostridium difficile infection: a retrospective single-center chart review. JGH Open. (2018) 3:4–9. 10.1002/jgh3.12093
    1. Hyvärinen K, Mäntylä P, Buhlin K, Paju S, Nieminen MS, Sinisalo J, et al. A common peridontal pathogen has an adverse association with both acute and stable coronary artery disease. Atherosclerosis. (2012) 223:478–84. 10.1016/j.atherosclerosis.2012.05.021
    1. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A. Detection of diverse bacterial signatures in atherosclerosis lesions of patients with coronary heart disease. Circulation. (2006) 113:929–37. 10.1161/CIRCULATIONAHA.105.579979
    1. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB. Colonic bacterial composition in Parkinson's disease. Mov Disord. (2015) 30:1351–60. 10.1002/mds.26307
    1. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. (2016) 167:1125–36.e8. 10.1016/j.cell.2016.10.020
    1. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MM, et al. . Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. (2016) 6:28484. 10.1038/srep28484
    1. Rubinstein MR, Wang X, Liu W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. (2013) 14:195–206. 10.1016/j.chom.2013.07.012
    1. Boleij A, Hechenbleikner EM, Goodwin AC. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. (2015) 60:208–15. 10.1093/cid/ciu787
    1. Scher JU, Sczesnak A, Longman R. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. (2013) 5:e01202 10.7554/eLife.01202
    1. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. (2015) 6:81. 10.3389/fphys.2015.00081
    1. Younes JA, Lievens E, Hummelen R, van der Westen R, Reid G, Petrova MI. Women and their microbes: the unexpected friendship. Trends Microbiol. (2018) 26:16–32. 10.1016/j.tim.2017.07.008
    1. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. . Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. (2011) 108 (Suppl. 1):4680–7. 10.1073/pnas.1002611107
    1. Paavonen J. Physiology and ecology of the vagina. Scand J Infect Dis Suppl. (1983) 40:31–5.
    1. Randelovic G, Mladenović V, Ristić L, Otašević S, Branković S, Mladenović-Antić S, et al. . Microbiological aspects of vulvovaginitis in prepubertal girls. Eur J Pediatr. (2012) 171:1203–8. 10.1007/s00431-012-1705-9
    1. Gupta S, Kumar N, Singhal N, Kaur R, Manektala U. Vaginal microflora in postmenopausal women on hormone replacement therapy. Indian J Pathol Microbiol. (2006) 49:457–61.
    1. Delaney ML, Onderdonk AB. Nugent score related to vaginal culture in pregnant women. Obstet Gynecol. (2001) 98:79–84. 10.1097/00006250-200107000-00015
    1. Gilbert SF, Sapp J, Tauber AI. A symbiotic view of life: we have never been individuals. Q Rev Biol. (2012) 87:325–41. 10.1086/668166
    1. Reid G. Cervicovaginal microbiome threats and possibilities. Trends Endocrinol Metab. (2016) 27:446–54. 10.1016/j.tem.2016.04.004
    1. Gosmann C, Anahtar MN, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA, et al. . Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. (2017) 46:29–37. 10.1016/j.immuni.2016.12.013
    1. Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L gasseri and/or L iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. (2009) 9:116. 10.1186/1471-2180-9-116
    1. Callahan BJ, Di Giulio DB, Goltsman DSA, Sun CL, Costello EK, Jeganathan P, et al. . Replication and refinement of a vaginal microbial signature of preterm birth in two racially distinct cohorts of US women. Proc Natl Acad Sci USA. (2017) 114:9966–71. 10.1073/pnas.1705899114
    1. Anahtar MN, Gootenberg DB, Mitchell CM, Kwon DS. Cervicovaginal microbiota and reproductive health: the virtue of simplicity. Cell Host Microbe._(2018) 23:159–68. 10.1016/j.chom.2018.01.013
    1. Fang RL, Chen LX, Shu WS, Yao SZ, Wang SW, Chen YQ. Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps. Am J Transl Res. (2016) 8:1581–92.
    1. Franasiak JM, Werner MD, Juneau CR, Tao X, Landis J, Zhan Y, et al. . Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit. J Assist Reprod Genet. (2016) 33:129–36. 10.1007/s10815-015-0614-z
    1. Haahr T, Jensen JS, Thomsen L, Duus L, Rygaard K, Humaidan P. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. (2016) 31:795–803. 10.1093/humrep/dew026
    1. Hyman RW, Herndon CN, Jiang H, Palm C, Fukushima M, Bernstein D, et al. . The dynamics of the vaginal microbiome during infertility therapy with in vitro fertilization-embryo transfer. J Assist Reprod Genet. (2012) 105–15. 10.1007/s10815-011-9694-6
    1. Chen C, Song XL, Wei WX, Zhong HZ, Dai JJ, Lan Z, et al. . The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. (2017) 8:875. 10.1038/s41467-017-00901-0
    1. Cicinelli E, Matteo M, Tinelli R, Pinto V, Marinaccio M, Indraccolo U, et al. . Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment. Reprod Sci. (2014) 21:640–7. 10.1177/1933719113508817
    1. Moreno I, Codoñer FM, Vilella F, Valbuena D, Martinez-Blanch JF, Jimenez-Almazán J, et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstet Gynecol. (2016) 215:684–703. 10.1016/j.ajog.2016.09.075
    1. Antonio MA, Rabe LK, Hillier SL. Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. J Infect Dis. (2005) 192:394–8. 10.1086/430926
    1. van de Wijgert JH, Verwijs MC, Turner AN, Morrison CS. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS. (2013) 27:2141–53. 10.1097/QAD.0b013e32836290b6
    1. Shen J, Song N, Williams CJ, Brown CJ, Yan Z, Xu C, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep. (2016) 6:24380 10.1038/srep24380
    1. Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact. (2009) 24:17 10.1186/1475-2859-8-17
    1. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. (2015) 16:137 10.1186/s12934-015-0313-6
    1. Medaglini D, Rush CM, Sestini P, Pozzi G. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine. (1997) 15:1330–7. 10.1016/S0264-410X(97)00026-1
    1. Kutteh WH, Kantele A, Moldoveanu Z, Crowley-Nowick PA, Mestecky J. Induction of specific immune responses in the genital tract of women after oral or rectal immunization and rectal boosting with Salmonella typhi Ty 21a vaccine. J Reprod Immunol. (2001) 52:61–75. 10.1016/S0165-0378(01)00109-7
    1. Kantele A, Häkkinen M, Moldoveanu Z, Lu A, Savilahti E, Alvarez RD, et al. . Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun. (1998) 66:5630–5.
    1. Kishimoto TK, Jutila MA, Butcher EC. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci USA. (1990) 87:2244–8. 10.1073/pnas.87.6.2244
    1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. (2007) 370:685–97. 10.1016/S0140-6736(07)61345-2
    1. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. (2004) 18:685–706. 10.1016/j.bpobgyn.2004.05.004
    1. Lindheim L, Bashir M, Münzker J, Trummer C, Zachhuber V, Leber B, et al. . Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS ONE. (2017) 12:e0168390. 10.1371/journal.pone.0168390
    1. Flak MB, Neves JF, Blumberg RS. Immunology. Welcome to the microgenderome. Science. (2013) 339:1044–5. 10.1126/science.1236226
    1. Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y. Association between polycystic ovary syndrome and gut microbiota. PLoS ONE. (2016) 11:e0153196. 10.1371/journal.pone.0153196
    1. Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)—a novel theory for the development ofPolycystic Ovarian Syndrome. Med Hypotheses. (2012) 79:104–12. 10.1016/j.mehy.2012.04.016
    1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. (2010) 362:2389–98. 10.1056/NEJMcp1000274
    1. Kobayashi H, Higashiura Y, Shigetomi H, Kajihara H. Pathogenesis of endometriosis: the role of initial infection and subsequent sterile inflammation. Mol Med Rep. (2014) 9:9–15. 10.3892/mmr.2013.1755
    1. Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. . Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med. (2012) 10:253. 10.1186/1479-5876-10-253
    1. Ata B, Yildiz S, Turkgeldi E, Brocal VP, Dinleyici EC, Moya A, et al. The endobiota study: comparison of vaginal, cervical and gut microbiota between women with stage 3/4 endometriosis and healthy controls. Sci Rep. (2019) 18:2204 10.1038/s41598-019-39700-6
    1. Marconi C, Cruciani F, Vitali B, Donders GG. Correlation of atopobium vaginae amount with bacterial vaginosis markers. J Low Genit Tract Dis. (2012) 16:127–32. 10.1097/LGT.0b013e31823c79c4
    1. Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med. (2018) 5:181. 10.3389/fmed.2018.00181
    1. Zariffard MR, Novak RM, Lurain N, Sha BE, Graham P, Spear GT. Induction of tumor necrosis factor-alpha secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J Infect Dis. (2005) 191:1913–21. 10.1086/429922
    1. Trinh HT, Lee IA, Hyun YJ, Kim DH. Artemisia princeps Pamp. Essential oil and its constituents eucalyptol and α-terpineol ameliorate bacterial vaginosis and vulvovaginal candidiasis in mice by inhibiting bacterial growth and NF-κB activation. Planta Med. (2011) 77:1996–2002. 10.1055/s-0031-1280094
    1. Kim DE, Kim JK, Han SK, Jang SE, Han MJ, Kim DH. Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 Alleviate Bacterial Vaginosis and Osteoporosis in Mice by Suppressing NF-κB-Linked TNF-α Expression. J Med Food. (2019) 22:1022–31. 10.1089/jmf.2019.4419
    1. Joo HM, Hyun YJ, Myoung KS, Ahn YT, Lee JH, Huh CS, et al. . Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-κB activation. Int Immunopharmacol. (2011) 11:1758–65. 10.1016/j.intimp.2011.07.002

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera